Schild, Y.; Bosserhoff, J.; Droege, F.; Littwitz-Salomon, E.; Fandrey, J.; Wrobeln, A.
Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor Improves Leukocyte Energy Metabolism in Hereditary Hemorrhagic Telangiectasia. Life 2023, 13, 1708.
https://doi.org/10.3390/life13081708
AMA Style
Schild Y, Bosserhoff J, Droege F, Littwitz-Salomon E, Fandrey J, Wrobeln A.
Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor Improves Leukocyte Energy Metabolism in Hereditary Hemorrhagic Telangiectasia. Life. 2023; 13(8):1708.
https://doi.org/10.3390/life13081708
Chicago/Turabian Style
Schild, Yves, Jonah Bosserhoff, Freya Droege, Elisabeth Littwitz-Salomon, Joachim Fandrey, and Anna Wrobeln.
2023. "Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor Improves Leukocyte Energy Metabolism in Hereditary Hemorrhagic Telangiectasia" Life 13, no. 8: 1708.
https://doi.org/10.3390/life13081708
APA Style
Schild, Y., Bosserhoff, J., Droege, F., Littwitz-Salomon, E., Fandrey, J., & Wrobeln, A.
(2023). Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor Improves Leukocyte Energy Metabolism in Hereditary Hemorrhagic Telangiectasia. Life, 13(8), 1708.
https://doi.org/10.3390/life13081708
